Epstein-Barr Virus: Activation of WNT

Epstein-Barr 病毒:WNT 激活

基本信息

项目摘要

DESCRIPTION (provided by applicant): The goal of this proposal is to characterize the effects of Epstein Barr Virus (EBV) on the Writ/Wingless signaling pathway which is a critical regulator of cell growth and differentiation during development and is frequently affected during cancer development. In this application, we will determine if this pathway is activated infected cell lines and in EBV-associated cancers, identify the viral proteins that affect regulation of this pathway, determine the mechanisms that underlie this activation, and identify the cellular targets that are affected by this activation. Specifically we will: 1) Characterize beta-catenin levels, localization, and activity in EBV positive and negative cell lines and in EBV-associated and AIDS-related cancers using cell fractionation and immunoblotting, electrophoretic mobility shift assays (EMSA) on beta-catenin responsive elements, reporter assays, and immunohistochemistry to identify specific phosphorylated protein components of the pathway and determine intracellular localization of beta-catenin. 2) Identify the effects of LMP 1 on expression and localization of components of writ/wingless using protein and gene array analyses. 3) Determine the effects of LMP2 on Akt activation, inactivation of glycogen synthase kinase beta, B-catenin localization, and wnt-regulated gene expression. Compare and contrast LMP2 with mutated forms of LMP2 and with constitutively activated forms of PI3-kinase and Akt. Determine the contribution of activation of this pathway on LMP2-mediated effects on cellular growth using fibroblast and epithelial cell transformation assays and perform genomic expression array analysis on cell lines expressing LMP2, mutant forms of LMP2, or activated components of wnt signaling to determine effects on gene expression. 4) Analyze LEF/TCF regulated gene expression in cell lines expressing EBV latent proteins. Identify components of the transcription complex and determine how EBV proteins affect this complex. The proposed studies represent the first studies on a completely new pathway likely affected in EBV-associated cancers. These studies will determine the contribution of this pathway in the development of EBV-associated cancers and identify the specific effects of EBV proteins on the regulation of wnt/wingless signaling. A detailed understanding of the activation of this pathway may provide new opportunities for treatment of EBV-associated cancers and also of similar cancers considered EBV-negative, that develop in the immunosuppressed.
描述(申请人提供):这项建议的目标是表征EB病毒(EBV)对WRIT/Wingless信号通路的影响,该信号通路是细胞发育过程中生长和分化的关键调节因子,经常在癌症发展过程中受到影响。在这项应用中,我们将确定这一途径是否被激活,在感染细胞系和EBV相关癌症中,识别影响这一途径调控的病毒蛋白,确定这种激活的机制,并确定受这种激活影响的细胞靶点。具体地说,我们将:1)通过细胞分级和免疫印迹、对β-连环蛋白反应元件的电泳迁移率改变分析(EMSA)、报告分析和免疫组织化学来鉴定该通路的特定磷酸化蛋白成分,并确定该通路的特定磷酸化蛋白成分,从而表征EBV阳性和阴性细胞系以及EBV相关和艾滋病相关癌症中的β-连环蛋白水平、定位和活性。2)利用蛋白质和基因芯片分析鉴定LMP-1对WRIT/WING基因表达和定位的影响。3)研究LMP2对Akt激活、糖原合成酶激酶β失活、B-连环蛋白定位以及WNT调控基因表达的影响。比较和对比LMP2与LMP2的突变形式以及PI3-激酶和Akt的结构性激活形式。通过成纤维细胞和上皮细胞转化实验,确定该通路的激活在LMP2介导的细胞生长效应中的作用,并对表达LMP2、LMP2的突变形式或WNT信号的激活成分的细胞系进行基因组表达阵列分析,以确定对基因表达的影响。4)分析LeF/TCF在表达EBV潜伏蛋白的细胞系中的调控基因表达。确定转录复合体的成分,并确定EBV蛋白如何影响该复合体。这项拟议的研究是对EBV相关癌症中可能受到影响的全新途径的首次研究。这些研究将确定这一途径在EBV相关癌症的发展中的作用,并确定EBV蛋白在Wnt/Wingless信号调节中的特定作用。对这一途径激活的详细了解可能会为治疗EBV相关癌症和被认为是EBV阴性的类似癌症提供新的机会,这些癌症发生在免疫抑制的人群中。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

NANCY JOAN RAAB-TRAUB其他文献

NANCY JOAN RAAB-TRAUB的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('NANCY JOAN RAAB-TRAUB', 18)}}的其他基金

Virology
病毒学
  • 批准号:
    8340212
  • 财政年份:
    2011
  • 资助金额:
    $ 31.72万
  • 项目类别:
Virology
病毒学
  • 批准号:
    8340213
  • 财政年份:
    2011
  • 资助金额:
    $ 31.72万
  • 项目类别:
EBV BART miRNAs: Identification of Targets and Characterization of the Effects o
EBV BART miRNA:目标鉴定和效应表征
  • 批准号:
    8386652
  • 财政年份:
    2009
  • 资助金额:
    $ 31.72万
  • 项目类别:
EBV BART miRNAs: Identification of Targets and Characterization of the Effects o
EBV BART miRNA:目标鉴定和效应表征
  • 批准号:
    8585832
  • 财政年份:
    2009
  • 资助金额:
    $ 31.72万
  • 项目类别:
EBV BART miRNAs: Identification of Targets and Characterization of the Effects o
EBV BART miRNA:目标鉴定和效应表征
  • 批准号:
    7785008
  • 财政年份:
    2009
  • 资助金额:
    $ 31.72万
  • 项目类别:
EBV BART miRNAs: Identification of Targets and Characterization of the Effects o
EBV BART miRNA:目标鉴定和效应表征
  • 批准号:
    7995263
  • 财政年份:
    2009
  • 资助金额:
    $ 31.72万
  • 项目类别:
EBV BART miRNAs: Identification of Targets and Characterization of the Effects o
EBV BART miRNA:目标鉴定和效应表征
  • 批准号:
    8196870
  • 财政年份:
    2009
  • 资助金额:
    $ 31.72万
  • 项目类别:
Herpesviral Oncogenesis, Latency and Reactivation
疱疹病毒肿瘤发生、潜伏期和再激活
  • 批准号:
    7908032
  • 财政年份:
    2009
  • 资助金额:
    $ 31.72万
  • 项目类别:
ADMINISTRATION CORE
管理核心
  • 批准号:
    6930192
  • 财政年份:
    2005
  • 资助金额:
    $ 31.72万
  • 项目类别:
TRANSFORMATION BY EBV LATENT MEMBRANE PROTEINS 1 AND 2
EBV 潜伏膜蛋白 1 和 2 的转化
  • 批准号:
    6930190
  • 财政年份:
    2005
  • 资助金额:
    $ 31.72万
  • 项目类别:

相似海外基金

Analysis of transmembrane proteins activity in urological cancers using humanized SCID mouse
使用人源化 SCID 小鼠分析泌尿系统癌症中的跨膜蛋白活性
  • 批准号:
    19K09674
  • 财政年份:
    2019
  • 资助金额:
    $ 31.72万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
SCID Mouse: Human Xenograft Core
SCID 小鼠:人类异种移植核心
  • 批准号:
    7608570
  • 财政年份:
    2008
  • 资助金额:
    $ 31.72万
  • 项目类别:
SCID Mouse : Human Xenograft Core
SCID 小鼠:人类异种移植核心
  • 批准号:
    7392297
  • 财政年份:
    2007
  • 资助金额:
    $ 31.72万
  • 项目类别:
Core B - SCID Mouse : Human Xenograft Core (Jordan Pober, MD/PhDP.I.)
核心 B - SCID 小鼠:人类异种移植核心(Jordan Pober,医学博士/博士)
  • 批准号:
    6756347
  • 财政年份:
    2004
  • 资助金额:
    $ 31.72万
  • 项目类别:
CORE--NOD/SCID MOUSE
核心--NOD/SCID鼠标
  • 批准号:
    6967796
  • 财政年份:
    2004
  • 资助金额:
    $ 31.72万
  • 项目类别:
EXPERIMENTAL ANALYSIS OF VASCULER CHANGES IN CHRONIC ALLOGRAFT REJECTION USING HUMANIZED SCID MOUSE MODEL.
使用人源化 SCID 小鼠模型对慢性同种异体移植排斥中的血管变化进行实验分析。
  • 批准号:
    14571526
  • 财政年份:
    2002
  • 资助金额:
    $ 31.72万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The heat shock protein(HSP) was investigated as the pathogenesis of focal infection with tonsil by the SCID mouse model
通过SCID小鼠模型研究热休克蛋白(HSP)作为扁桃体局灶性感染的发病机制
  • 批准号:
    14571629
  • 财政年份:
    2002
  • 资助金额:
    $ 31.72万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Establishment of patient-like SCID mouse model by orthotopically implanting primary cultured cells from surgically-resected lung cancer tissues.
通过原位植入手术切除的肺癌组织的原代培养细胞建立类患者 SCID 小鼠模型。
  • 批准号:
    14571269
  • 财政年份:
    2002
  • 资助金额:
    $ 31.72万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CORE--NUDE/SCID MOUSE FACILITY
核心——NUDE/SCID 小鼠设施
  • 批准号:
    6563716
  • 财政年份:
    2001
  • 资助金额:
    $ 31.72万
  • 项目类别:
CORE--NOD/SCID MOUSE
核心--NOD/SCID鼠标
  • 批准号:
    6496710
  • 财政年份:
    2001
  • 资助金额:
    $ 31.72万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了